Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
A parallel “year of truth” roadmap for Iovance Biotherapeutics (IOVA), ImmunityBio (IBRX) and Altimmune (ALT), three names with huge retail followings, real science on the table and very little room for execution mistakes.
Wall Street just closed a choppy week where enthusiasm about AI and data-center spend ran into valuation nerves, while inflation data kept the “soft landing” narrative alive. The coming days will be dominated by U.S. GDP, the Fed’s preferred inflation gauge (core PCE), fresh PMIs and a cluster of sector-specific catalysts across biotech, space, defense and AI small/mid caps.
The logic of this basket is to follow the AI value chain from data to models to deployment, without touching the mega-cap hyperscalers. Each ticker is plugged into a different piece of that chain: some provide platforms, some sell services, some sell hardware that enables AI workloads.
A simple way to think about this basket is to imagine the space stack as layers: access to orbit, sensing, communications, infrastructure and exploration. Each of the ten names here owns a useful slice of that stack, often in niches that the mega-caps either do not want or cannot address efficiently.
The big defense primes will always dominate the headlines, but the real optionality for capital gains usually sits one step below, in the names that own a niche. In this basket the niches are clear: tactical drones and loitering munitions (KTOS, AVAV), hypersonic testing and missile-defense space constellations (KTOS, RKLB), naval power and combat systems (DRS), training and simulation (CAE), advanced composites (HXL), electronic-warfare computers (MRCY), spectrum and cyber for national security (CACI, SAIC) and high-margin aerospace components (HEI).
A post-CRL, post-Type A meeting request deep dive on ONS-5010/LYTENAVA, EU/UK launch reality, funding pressure and how much option value is left in a sub-$35M market cap.
Big Pharma is heading into a new patent cliff while its in-house pipelines struggle to keep up. That makes small and mid-cap biotech one of the most fertile hunting grounds for both acquisitions and high-beta “run-up” trades ahead of binary events like FDA decisions and pivotal clinical readouts. In this note we highlight ten US-listed biotech names under roughly $2 billion in market cap that all have a clearly defined catalyst between now and the end of June 2026.
In the last 30 days the “space trade” has flipped from poster child of risk-on to textbook case of brutal risk-off. Launch, satcom and geospatial names are bleeding double-digit days, while some defense-linked players hold up. Under the surface, it is a story of funding, dilution anxiety, macro rates and a sector where AI and defense still pull in structural demand.
Key idea. In January we framed Neumora as a post-crash special situation: a neuroscience platform that had just blown up its lead asset navacaprant in Phase 3 MDD, wiping out about 80% of the market cap in one session, but still sitting on a sizeable cash pile and a broad pipeline. The weeks since then have added three crucial pieces: (1) full Phase 1b signal-seeking data for NMRA-511 in Alzheimer’s agitation, (2) a more detailed 2026 pipeline strategy, and (3) better visibility on ownership, institutional support and analyst appetite post-crash. This second deep dive doesn’t repeat the full story — it extends it and tries to answer a simple question: is NMRA slowly rebuilding a credible equity story, or just trading on residual hope and short-term speculation?
Jiade is a micro-cap education-support company listed on Nasdaq, best known for providing tutoring and training services for adult and vocational education in China. A strategic cooperation with a South Korea–based AI education brand adds an international angle, but the story still sits at the intersection of cross-border ambitions, regulatory risk and the harsh math of small-cap liquidity.
Viking has just reported fourth-quarter and full-year 2025 numbers and given a dense update on its obesity and metabolic pipeline. The picture is clear: spending is ramping, the cash pile is still very strong, and the company is steering both injectable and oral VK2735 toward the next wave of pivotal trials while preparing a new amylin program and keeping VK2809/VK0214 alive in the background.
The core idea is blunt but useful: markets are paying up for the “picks and shovels” of AI – chips, foundry, high-bandwidth memory, data centres, cybersecurity, observability – and they are putting a heavy discount on businesses whose main value proposition can be replicated by AI agents, plug-ins and low-cost automation. It is not just about which tickers are in fashion; it is about which roles and workflows are becoming cheaper to automate.
Why this Daily Hit, if Moderna is not a small biotech?
Moderna is obviously not a small-cap biotech living hand-to-mouth. Yet the refusal-to-file (RTF) letter that the U.S. Food and Drug Administration (FDA) just sent for its seasonal flu vaccine mRNA-1010 is such an outlier in terms of process and signalling that it deserves a dedicated “hit” article.
Denali Therapeutics is moving into the most delicate phase of its evolution: from a blood–brain-barrier platform story to a commercial-stage rare-disease company. The centre of gravity is tividenofusp alfa (DNL310), a TransportVehicle-enabled enzyme replacement therapy for Hunter syndrome (MPS II) designed to address both systemic and central nervous system manifestations, something that current standard ERTs cannot do.
TuHURA announces that Kintara’s REM-001 trial in metastatic cutaneous breast cancer has met its primary safety endpoint in ten patients with early signs of clinical efficacy. This triggers the contractual milestone under the Kintara CVR Agreement and unlocks the distribution of 1,539,958 HURA shares to legacy Kintara shareholders holding CVRs.
Updated preliminary Phase I/IIa data in Fabry disease show sustained, dose-dependent α-Gal A activity far above normal and allow enzyme-replacement withdrawal in more than half of treated patients, while safety findings trigger a pause in higher-dose cohorts. At the same time, AMT-130 for Huntington’s disease faces a tougher regulatory path after FDA feedback that current Phase I/II data are unlikely to support a BLA as primary evidence. This report connects Fabry, Huntington and the broader AAV5 platform story under the lens of balance sheet, catalyst map, key risks and retail sentiment.
Maze trades as a high-expectations play on APOL1-mediated kidney disease: the stock has rerated into a roughly mid-cap valuation on the back of a very strong balance sheet and the upcoming proof-of-concept data from the HORIZON Phase 2 trial in a broad AMKD population. The key tension now is simple: can the first substantive MZE829 dataset justify how far the share price has already come.
In January you saw the “National Defense Strategy / Deep Tech” macro piece: defense budgets, uranium enrichment, electronic warfare and reusable launch infrastructure all moving at once. In that map, AST SpaceMobile sits on the space-based connectivity layer: a company trying to build cell towers in orbit that can serve both civilian and military customers, at a time when governments explicitly talk about resilient communications, contested environments and independent infrastructure. This note takes that macro lens and zooms back into ASTS.
The FDA has sent a Complete Response Letter (CRL) for RGX-121 (clemidsogene lanparvovec) in MPS II, rejecting the BLA under the accelerated approval pathway and questioning the external control, the neuronopathic eligibility criteria and the CSF HS D2S6 biomarker. Management plans a Type A meeting and aims to resubmit, but the ultra-rare MPS II path is now longer and more complex, against a backdrop of recent clinical holds on the company’s ultra-rare MPS programs.
Quince Therapeutics has announced that it has engaged LifeSci Capital as its exclusive financial advisor to assist with a restructuring process and a formal review of “strategic alternatives” with the stated goal of maximizing shareholder value. The menu of options explicitly listed by the company includes partnerships, joint ventures, mergers, acquisitions, licensing deals or other strategic transactions, and LifeSci will also support any restructuring of the company’s liabilities.